Gil M. Labrucherie
2018
In 2018, Gil M. Labrucherie earned a total compensation of $5.7M as Senior Vice President and Chief Financial Officer at Nektar Therapeutics, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $631,600 |
|---|---|
| Option Awards | $2,359,382 |
| Salary | $631,696 |
| Stock Awards | $2,099,320 |
| Other | $11,930 |
| Total | $5,733,928 |
Labrucherie received $2.4M in option awards, accounting for 41% of the total pay in 2018.
Labrucherie also received $631.6K in non-equity incentive plan, $631.7K in salary, $2.1M in stock awards and $11.9K in other compensation.
Rankings
In 2018, Gil M. Labrucherie's compensation ranked 1,673rd out of 14,244 executives tracked by ExecPay. In other words, Labrucherie earned more than 88.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,673 out of 14,244 | 88th |
Division Manufacturing | 595 out of 5,765 | 90th |
Major group Chemicals And Allied Products | 190 out of 2,128 | 91st |
Industry group Drugs | 151 out of 1,817 | 92nd |
Industry Pharmaceutical Preparations | 112 out of 1,391 | 92nd |
Source: SEC filing on April 30, 2019.
Labrucherie's colleagues
We found four more compensation records of executives who worked with Gil M. Labrucherie at Nektar Therapeutics in 2018.
2018
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2018
Jillian Thomsen
Nektar Therapeutics
Chief Accounting Officer
2018
Stephen Doberstein
Nektar Therapeutics
Chief Research and Development Officer
2018
Maninder Hora
Nektar Therapeutics